Research graph
References from Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs. Local targets link to admitted publications; unresolved targets remain external evidence.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
10.1093/eurheartj/ehab368 · 2021 · External reference
Heart failure drug treatment: the fantastic four
10.1093/eurheartj/ehaa1012 · 2021 · External reference
2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
10.1093/eurheartj/ehad195 · 2023 · External reference
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
10.1016/s0140-6736(22)02076-1 · 2022 · External reference
A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction
10.1002/ehf2.14197 · 2023 · External reference
Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy
10.1093/eurheartj/ehaf244 · 2025 · External reference
How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC
10.1002/ejhf.3295 · 2024 · External reference
From prescription to persistence: guideline-recommended medical therapy in heart failure with reduced ejection fraction
10.1093/eurheartj/ehag198 · 2026 · External reference
Management of worsening heart failure with reduced ejection fraction: JACC focus seminar 3/3
10.1016/j.jacc.2023.04.057 · 2023 · External reference
The year in cardiovascular medicine 2025: the top 10 papers in heart failure
10.1093/eurheartj/ehaf1044 · 2026 · External reference
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial
10.1016/s0140-6736(25)01665-4 · 2025 · External reference
Digitoxin in patients with heart failure and reduced ejection fraction
10.1056/nejmoa2415471 · 2025 · External reference
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial
10.1093/eurheartj/ehaf655 · 2026 · External reference
Digitalis—back on centre stage for HFrEF
10.1093/ejhf/xuaf002 · 2026 · External reference
Beyond the 4 pillars: where does vericiguat stand in contemporary HFrEF care?
10.1016/j.jacc.2025.10.040 · 2025 · External reference
